New BlueFletch Healthcare solution transforms clinical workflow efficiency while supporting healthcare organizations' regulatory compliance requirements
Read More
The untold truth? Rescheduling may not save the cannabis industry-it could divide it.
Past IRS 280E tax liabilities won't vanish-some companies owe hundreds of millions.
Interstate cannabis operators still remain barred from DEA licensing, regardless of tax changes.
Marijuana is still DEA regulated under the Controlled Substance Act and
The combined net Q2 2025 revenue of approximately $3.0 million for prescription and non-prescription products, including license revenue, increased approximately 35% versus net Q1 2025 revenue of approximately $2.2 million and increased approximately 10% versus net Q2 2024 revenue of approximately $2.7 million
Mytesi prescription volume increased approximately 6.5% in Q2 2025 over Q1 2025 and Mytesi prescription volume in Q2 2025 was equal to the volume in Q2 2024
As announced, initial proof-of-concept results from the ongoing investigator-initiated trial in Abu Dhabi show crofelemer reduced the required total parenteral nutrition in the first participating microvillus inclusion disease (MVID) patient by up to 27% and in the first participating short bowel syndrome (SBS-IF) patient by up to 12.5%; FDA meeting resulted in planned Jaguar regulatory pathway to complete supplemental NDA strategy for crofelemer for patients with metastatic breast cancer, a population meeting orphan definition in US
Company strategy: Seek business development partnerships for license to develop and commercialize Jaguar's orphan indication products, resulting in non-dilutive funding for Jaguar
REMINDER: Today Jaguar to host investor webcast at 8:30 a.m. Eastern regarding Q2 2025 financials and company updates; Click here to register
Read MoreCompany Reports Quarterly Revenue of $1.2 Million; Net Loss and Loss per Diluted Share of $2.2 Million and $2.13
Quarterly Adjusted EBITDA Loss of $1.7 Million Reflects 40% YOY Improvement
TRNR held 29.6 Million FET tokens as of June 30, 2025 and 67.4 Million FET tokens as of August 13, 2025, with a value in excess of $50 million, representing the largest publicly traded AI-focused Digital Asset Treasury
Stockholders' Equity Was $16.3 Million at Quarter End
2025 Pro Forma Revenue Guidance Increased to more than $80 Million, driven by Sportstech's Stronger-Than-Expected Performance, and Fourth Quarter Profitability Guidance Reiterated
Read More- Dermata announced additional positive data from its XYNGARI™ Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial-
- Raised $8.8 million in gross proceeds from a private placement and warrant inducement financings during the first half of 2025 -
Read MoreInitiates Critical Milestone, Launching Phase 3 Trial of PF614 to Advance Next-Generation Opioid Therapy Toward Regulatory Approval
Receives $5.3 Million Installment from NIDA To Support Overdose Protection Program
Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2
Read More
BUZZ BOMB™ is bringing its unique delivery technology benefits to the multi-billion-dollar pre-workout to help athletes and fitness enthusiasts maximize their performance potential
30,000 BUZZ BOMB™ sample packs of four 50mg stick packs in each flavor distributed to convention attendees
Well-known fitness instructors, fitness celebrities, athletes, and influencers along with thousands of fitness enthusiasts and consumers sampled BUZZ BOMB™'s four bold flavors
As part of its launch, Aspire plans on partnering with well-known athletes and influencers across fitness training and endurance sports to accelerate consumer awareness and uptake
BUZZ BOMB™ is available for purchase at buzzbomb.buzz, the Company's new E-commerce website
Builds on the targeted immune activation model validated by mipletamig in AML, adapted for prostate cancer.
Engineered for precision T-cell activation in prostate cancer; part of Aptevo's growing CRIS-7-derived CD3 portfolio targeting both hematologic and solid tumors
Read More
A fellowship-trained foot and ankle surgeon with expertise in reconstruction, sports injuries, and limb salvage, Dr. Talisse brings advanced care to three South Metro Atlanta locations.
Read More
Positions IGC at the intersection of biotech innovation and cannabinoid science in one of the largest unmet medical needs in the world
Alzheimer's affects over 50 million people globally, with more than 400 million at risk from underlying disease pathology
Click here to register
Company plans to file its Earnings Report on August 14, 2025 on Form 10-Q for the quarter ended June 30, 2025
Jaguar CEO Lisa Conte presenting August 20 at Emerging Growth Conference to provide updates on near-term catalysts; Click here to register
Read MoreManuscript accepted for publication in Frontiers in Pharmacology, "Oral Administration of Ketamir-2, a Novel Ketamine Analog, Attenuates Neuropathic Pain in Rodent Models via Selective NMDA Antagonism" details Ketamir-2's superior performance in two validated neuropathic pain models and supports advancement to Phase 2a clinical trials by year-end 2025.
Read More
MMJ BioPharma is taking its fight for FDA approved cannabis medicine directly to DEA Administrator Terry Cole, as President Trump signals openness to marijuana's medical benefits. After seven years of delays, MMJ is ready to launch clinical trials for Huntington's disease and Multiple Sclerosis- if the DEA finally issues its long overdue API Bulk manufacturing registration.
Read MoreMipletamig's 85% frontline AML remission rate and favorable safety profile drive APVO's differentiated CD3 portfolio expansion with APVO455, a Nectin-4 x CD3 bispecific for multiple solid tumor types
CD3 bispecific portfolio now includes three candidates - mipletamig (AML), APVO442 (prostate cancer), and newly added APVO455 - advancing a targeted, tumor-specific strategy uniquely engineered for safety, tumor specificity and clinical impact
Mipletamig, continues to outperform benchmarks, trial enrollment continues
$15.9 million raised in 2Q25, extending cash runway into late 4Q25
Read More
Trump said his administration will focus on research to unlock the medical uses of marijuana, and other priorities the marijuana industry has sought. However, will employees within the DEA continue trying to block President Trumps marijuana orders?
Read More
Terrance Cole's Choice: Reformer or Cover-Up Artist? New DEA Administrator Terrance Cole stands at a crossroads:
Break rank, clean house, and restore the DEA's marijuana research credibility by approving MMJ BioPharma's application.
Or protect the old guard's corruption-and go down as the next puppet in a failed prohibitionist machine.
Quotes From Inside the Agency Reveal Systemic Corruption, Regulatory Negligence, and Public Health Betrayal.
The DEA's war on cannabis research is not just a failure of policy-it's a failure of morality.
Read More
